Patheon adds capability to conduct cell-based assays
Patheon, a global provider of drug development and manufacturing services to the pharmaceutical industry, has added cell-based assay services to support biopharmaceutical product development.
Patheon, a global provider of drug development and manufacturing services to the pharmaceutical industry, has added cell-based assay services to support biopharmaceutical product development.
Cell-based assays are a key technology used in determining the biological potency of biopharmaceuticals required for product licensing procedures. Biological potency analytics and the required supporting capabilities for tissue culture, such as assessment of cell viability and production of master and working cell banks, will take place at Patheon's Swindon facility in the UK. This will enable all the analytical needs for biopharmaceutical product development to be completed in one location.
Wes Wheeler, president and chief executive of Patheon, said: "This new capability allows us better to meet the needs of customers in the early stages of drug development."
The facility will be managed and supported by a team of scientists with experience in tissue culture and cell-based assays. The facility will be fully available for use at the end of May.